Re­ci­pharm’s new CEO on ‘fast and fu­ri­ous’ changes, with eyes on GLP-1, bi­o­log­ics man­u­fac­tur­ing

Just over three months in­to his new role as the CEO of Re­ci­pharm, Greg Be­har is al­ready mak­ing siz­able changes to the CD­MO’s en­gine.

“I’ve been study­ing the com­pa­ny deeply be­fore join­ing so that we could move fast and fu­ri­ous on the first of Jan­u­ary, and that’s what we’ve been do­ing,” Be­har told End­points News in an in­ter­view.

Ac­cord­ing to the CEO, the com­pa­ny’s re­cent moves re­flect its ef­forts to sim­pli­fy its port­fo­lio. A few weeks ago, Re­ci­pharm di­vest­ed sev­en man­u­fac­tur­ing sites that will be­come a new, yet-to-be-named CD­MO un­der Blue Wolf Cap­i­tal Part­ners. In No­vem­ber, Re­ci­pharm said it would spin out its in­haler busi­ness to be­come a sep­a­rate com­pa­ny al­to­geth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER